Report overview
Drug therapy is currently the core method of treating bipolar disorder, that is, the use of emotional stabilizers to adjust the patient's mood. Bipolar disorder is complex and difficult to control. The drug effect of emotional stabilizers can help patients to suppress their emotions when they are too high, to increase their emotions when they are depressed, to stabilize their emotions at a normal level, and to effectively prevent the recurrence of bipolar disorder. The quickest and most effective approach may be convulsive-free electroconvulsive therapy.
This report contains market size and forecasts of Bipolar Disorder Drugs and Treatment in global, including the following market information:
Global Bipolar Disorder Drugs and Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Bipolar Disorder Drugs and Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Bipolar Disorder Drugs and Treatment companies in 2021 (%)
The global Bipolar Disorder Drugs and Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Mood Stabilizers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Bipolar Disorder Drugs and Treatment include AbbVie Inc., Glaxo SmithKline (GSK), Eli Lily and Company, Janssen Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc, Bristol Myers Squibb, Gedeon Richter PLC. and H. Lundbeck A/S, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Bipolar Disorder Drugs and Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bipolar Disorder Drugs and Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bipolar Disorder Drugs and Treatment Market Segment Percentages, by Type, 2021 (%)
Mood Stabilizers
Anticonvulsants
Antipsychotic Drugs
Antidepressant Drugs
Anti-Anxiety Drugs
Global Bipolar Disorder Drugs and Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bipolar Disorder Drugs and Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Bipolar Disorder Drugs and Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Bipolar Disorder Drugs and Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bipolar Disorder Drugs and Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Bipolar Disorder Drugs and Treatment revenues share in global market, 2021 (%)
Key companies Bipolar Disorder Drugs and Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Bipolar Disorder Drugs and Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Glaxo SmithKline (GSK)
Eli Lily and Company
Janssen Pharmaceuticals
Johnson & Johnson
Astellas Pharma Inc
Bristol Myers Squibb
Gedeon Richter PLC.
H. Lundbeck A/S
Pfizer Inc.
Novartis AG
Otsuka Holdings Co. Ltd
Validus Pharmaceuticals LLC.
